Punchline: From a single breakthrough to a scalable platform, GLP-1s have redefined Lillys business, positioning the company at the center of a new metabolic category.
These drugs are very effective at treating obesity and diabetes, and also reduce risk of heart disease and progression of kidney disease
2 Materials and Methods This systematic review was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [10]
Additionally, 43.2% of patients on the high dose reported nausea and 33.1% reported diarrhea, compared with 10.7% and 13.4% in the placebo group
Patients can schedule a consultation to discuss their goals, medical history, current options, and whether a medically guided weight-loss plan is appropriate
That is not a minor difference